Phoenix Asia Holdings Limited announced it will acquire 100% of ACEA Pharma, a clinical-stage pharmaceutical company, by issuing 100 million new shares valued at $1 billion. The acquisition is expected to close in Q2 2026, pending regulatory approvals including antitrust and Nasdaq clearance. Additionally, Phoenix Asia issued a $20 million convertible promissory note to its controlling shareholder as payment for advisory services. This marks Phoenix Asia's strategic shift from construction to becoming a pharmaceutical holding company.
Halper Sadeh LLC is investigating whether shareholders of Simulations Plus (SLP), Huntsman Corporation (HUN), Olin Corporation (OLN), and Pulmatrix (PULM) are receiving fair deals in recent mergers and sales. The firm suspects insiders may gain finan...
LB Pharmaceuticals has granted Christopher Zergebel, its new Senior Vice President of Clinical Operations, an inducement equity award of 75,000 stock options. The options have a ten-year term, an exercise price of $32.95 per share, and vest over four...
YSX Tech Co., Ltd announced a 16.8% revenue increase to $83.5 million for fiscal year 2026, driven by a 28.8% rise in service volumes, especially in vehicle risk screening services which grew 112.1%. The company shifted focus from individual insuranc...
UBS Group AG has notified Bang & Olufsen A/S that its shareholding and voting rights have dropped below the 5% threshold, holding 4.85% as of July 8, 2026. This update is in accordance with the Danish Capital Markets Act, which requires disclosure wh...
Assassin’s Creed Black Flag Resynced, a remake of the 2013 original, sold 2 million copies on its first day, marking a strong launch for Ubisoft. The game achieved the highest concurrent player count ever for the franchise on Steam and topped Twitch ...
